Uncorrected Proof scheduled for 18 (1)

Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia

Authors Information
Article Notes and Dates
To Cite : Jancoriene L, Polubenko K, Kazenaite E, Buivydiene A, Jakutiene J, et al. Direct-Acting Antivirals Ombitasvir / Paritaprevir / Ritonavir + Dasabuvir with or Without Ribavirin in Hepatitis C Virus (HCV) Genotype 1-Infected Treatment-Naive or Treatment-Experienced Patients with or Without Cirrhosis: Real-Life Experience in Lithuania and Latvia, Hepat Mon. Online ahead of Print ;In Press(In Press):e62105. doi: 10.5812/hepatmon.62105.
Copyright: Copyright © 0, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
References
  • 1. Zare F, Fattahi MR, Sepehrimanesh M, Safarpour AR. Economic Burden of Hepatitis C Virus Infection in Different Stages of Disease: A Report From Southern Iran. Hepat Mon. 2016; 16(4): 32654[DOI][PubMed]
  • 2. Fattahi MR, Safarpour A, Sepehrimanesh M, Hosseini Asl SM, Mohamaddoust F. The prevalence of hepatitis C virus infection and its related risk factors among the rural population of fars province, southern iran. Hepat Mon. 2015; 15(2): 24734[DOI][PubMed]
  • 3. Shamsdin SA, Sepehrimanesh M, Pezeshki B, Nejabat M. Seroprevalence of hepatitis B and C in patients with hemophilia: A single-centre descriptive study. Shiraz E-Med J. 2015; 16(7): 24573
  • 4. World Health Organization. . Global report on access to hepatitis C treatment. Focus on overcoming barriers. 2016;
  • 5. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015; 61(1): 77-87[DOI][PubMed]
  • 6. Alter HJ. HCV natural history: the retrospective and prospective in perspective. J Hepatol. 2005; 43(4): 550-2[DOI][PubMed]
  • 7. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006; 55(9): 1350-9[DOI][PubMed]
  • 8. Verna EC, Shetty K, Lukose T, Terry N, Mentore K, Olsen SK, et al. High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. Liver Int. 2015; 35(2): 510-7[DOI][PubMed]
  • 9. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis. 2012; 54(1): 96-104[DOI][PubMed]
  • 10. Feeney ER, Chung RT. Antiviral treatment of hepatitis C. BMJ. 2014; 348[DOI][PubMed]
  • 11. Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med. 2012; 366(3): 273-5[DOI][PubMed]
  • 12. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014; 147(2): 359-365 e1[DOI][PubMed]
  • 13. Deeks ED. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection. Drugs. 2015; 75(9): 1027-38[DOI][PubMed]
  • 14. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370(17): 1594-603[DOI][PubMed]
  • 15. Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2016; 64(2): 301-7[DOI][PubMed]
  • 16. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370(21): 1983-92[DOI][PubMed]
  • 17. Klibanov OM, Gale SE, Santevecchi B. Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection. Ann Pharmacother. 2015; 49(5): 566-81[DOI][PubMed]
  • 18. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014; 370(21): 1973-82[DOI][PubMed]
  • 19. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370(17): 1604-14[DOI][PubMed]
  • 20. European Association for Study of L. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015; 63(1): 199-236[DOI][PubMed]
  • 21. Lankarani KB, Ardebili M, Sepehrimanesh M, Nejabat M, Hemmati Rad MA, Hosseini SY. Evaluation of hepatitis C virus intrafamilial transmission among families with one index case, a pilot study from Fars province, Iran. Gastroenterol Hepatol Bed Bench. 2016; 9(4): 250-8[PubMed]
  • 22. Chamorro-de-Vega E, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, Escudero-Vilaplana V, Collado Borrell R, Ibanez-Garcia S, et al. Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice. Ann Pharmacother. 2016; 50(11): 901-8[DOI][PubMed]
  • 23. Chirino-Sprung RA, Dehesa M, Wolpert E, Corona-Lau C, Garcia-Juarez I, Sanchez-Avila JF, et al. Chronic Hepatitis C Treatment with Direct-Acting Antiviral Agents in a Real-Life Setting. Rev Invest Clin. 2016; 68(4): 203-12[PubMed]
  • 24. Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarebska-Michaluk D, Nazzal K, et al. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther. 2016; 44(9): 946-56[DOI][PubMed]
  • 25. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown RJ, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014; 371(25): 2375-82[DOI][PubMed]
  • 26. Pogorzelska J, Flisiak R. Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection. Clin Exp Hepatol. 2016; 2(2): 34-7[DOI][PubMed]
  • 27. Tronina O, Durlik M, Wawrzynowicz-Syczewska M, Buivydiene A, Katzarov K, Kupcinskas L, et al. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir+/-Ribavirin (OBV/PTV/r/+DSV+/-RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. Ann Transplant. 2017; 22: 199-207[PubMed]
  • 28. Wedemeyer H, Craxi A, Zuckerman E, Dieterich D, Flisiak R, Roberts SK, et al. Real-world effectiveness of ombitasvir/paritaprevir/ritonavir+/-dasabuvir+/-ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis. J Viral Hepat. 2017; 24(11): 936-43[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By: